Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225


The landscape of hepatobiliary adverse reactions across 53 herbal and dietary supplements reveals immune-mediated injury as a common cause of hepatitis.

Zhu J, Chen M, Borlak J, Tong W.

Arch Toxicol. 2019 Nov 13. doi: 10.1007/s00204-019-02621-4. [Epub ahead of print]


Hepatobiliary Events in Migraine Therapy with Herbs-The Case of Petadolex, A Petasites Hybridus Extract.

Anderson N, Borlak J.

J Clin Med. 2019 May 10;8(5). pii: E652. doi: 10.3390/jcm8050652.


Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease.

Breher-Esch S, Sahini N, Trincone A, Wallstab C, Borlak J.

BMC Med Genomics. 2018 Dec 14;11(1):111. doi: 10.1186/s12920-018-0438-7.


The Development of a Database for Herbal and Dietary Supplement Induced Liver Toxicity.

Zhu J, Seo JE, Wang S, Ashby K, Ballard R, Yu D, Ning B, Agarwal R, Borlak J, Tong W, Chen M.

Int J Mol Sci. 2018 Sep 28;19(10). pii: E2955. doi: 10.3390/ijms19102955.


Serum proteome mapping of EGF transgenic mice reveal mechanistic biomarkers of lung cancer precursor lesions with clinical significance for human adenocarcinomas.

Borlak J, Länger F, Chatterji B.

Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3122-3144. doi: 10.1016/j.bbadis.2018.06.019. Epub 2018 Jun 28.


Treatment of cyclosporine induced hypertension: Results from a long-term observational study using different antihypertensive medications.

Marienhagen K, Lehner F, Klempnauer J, Hecker H, Borlak J.

Vascul Pharmacol. 2019 Apr;115:69-83. doi: 10.1016/j.vph.2018.06.012. Epub 2018 Jun 19.


Review article: therapeutic bile acids and the risks for hepatotoxicity.

Ashby K, Navarro Almario EE, Tong W, Borlak J, Mehta R, Chen M.

Aliment Pharmacol Ther. 2018 Jun;47(12):1623-1638. doi: 10.1111/apt.14678. Epub 2018 Apr 27. Review.


The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury.

Selvaraj S, Oh JH, Spanel R, Länger F, Han HY, Lee EH, Yoon S, Borlak J.

Oncotarget. 2017 Sep 23;8(64):107763-107824. doi: 10.18632/oncotarget.21201. eCollection 2017 Dec 8.


ApoE is a major determinant of hepatic bile acid homeostasis in mice.

von Hardenberg S, Gnewuch C, Schmitz G, Borlak J.

J Nutr Biochem. 2018 Feb;52:82-91. doi: 10.1016/j.jnutbio.2017.09.008. Epub 2017 Sep 28.


N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury.

Borlak J, van Bömmel F, Berg T.

Liver Int. 2018 Feb;38(2):365-376. doi: 10.1111/liv.13538. Epub 2017 Sep 8.


A unifying mathematical model of lipid droplet metabolism reveals key molecular players in the development of hepatic steatosis.

Wallstab C, Eleftheriadou D, Schulz T, Damm G, Seehofer D, Borlak J, Holzhütter HG, Berndt N.

FEBS J. 2017 Oct;284(19):3245-3261. doi: 10.1111/febs.14189. Epub 2017 Sep 6.


Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.

McEuen K, Borlak J, Tong W, Chen M.

Int J Mol Sci. 2017 Jun 22;18(7). pii: E1335. doi: 10.3390/ijms18071335.


Primary non-function is frequently associated with fatty liver allografts and high mortality after re-transplantation.

Kulik U, Lehner F, Klempnauer J, Borlak J.

Liver Int. 2017 Aug;37(8):1219-1228. doi: 10.1111/liv.13404. Epub 2017 May 15.


Drug-Induced Liver Injury.

Almario EE, Borlak J, Suzuki A, Chen M.

Biomed Res Int. 2017;2017:2461694. doi: 10.1155/2017/2461694. Epub 2017 Jan 9. No abstract available.


In vitro to in vivo extrapolation for drug-induced liver injury using a pair ranking method.

Liu Z, Fang H, Borlak J, Roberts R, Tong W.

ALTEX. 2017;34(3):399-407. doi: 10.14573/altex.1610201. Epub 2017 Jan 11.


Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects.

Zwadlo C, Borlak J.

Vascul Pharmacol. 2016 Dec;87:121-128. doi: 10.1016/j.vph.2016.09.001. Epub 2016 Sep 6.


c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.

Ciribilli Y, Singh P, Inga A, Borlak J.

Oncotarget. 2016 Oct 4;7(40):65514-65539. doi: 10.18632/oncotarget.11804.


A Model to predict severity of drug-induced liver injury in humans.

Chen M, Borlak J, Tong W.

Hepatology. 2016 Sep;64(3):931-40. doi: 10.1002/hep.28678. Epub 2016 Jul 27.


Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC.

Ritorto MS, Rhode H, Vogel A, Borlak J.

Biol Chem. 2016 Nov 1;397(11):1147-1162. doi: 10.1515/hsz-2016-0133.


Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.

Borlak J, Länger F, Spanel R, Schöndorfer G, Dittrich C.

Oncotarget. 2016 May 10;7(19):28059-74. doi: 10.18632/oncotarget.8574.


Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades.

Liu Z, Wang Y, Borlak J, Tong W.

Sci Rep. 2016 Apr 5;6:23709. doi: 10.1038/srep23709.


Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.

Zhang J, He K, Cai L, Chen YC, Yang Y, Shi Q, Woolf TF, Ge W, Guo L, Borlak J, Tong W.

Chem Biol Interact. 2016 Aug 5;255:45-54. doi: 10.1016/j.cbi.2016.03.019. Epub 2016 Mar 19.


Immunogenomics reveal molecular circuits of diclofenac induced liver injury in mice.

Lee EH, Oh JH, Selvaraj S, Park SM, Choi MS, Spanel R, Yoon S, Borlak J.

Oncotarget. 2016 Mar 22;7(12):14983-5017. doi: 10.18632/oncotarget.7698.


Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.

Zhang J, Doshi U, Suzuki A, Chang CW, Borlak J, Li AP, Tong W.

Chem Biol Interact. 2016 Aug 5;255:3-11. doi: 10.1016/j.cbi.2015.11.008. Epub 2015 Nov 12.


Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.

Ciribilli Y, Singh P, Spanel R, Inga A, Borlak J.

Oncotarget. 2015 Oct 13;6(31):31569-92. doi: 10.18632/oncotarget.5035.


Drug-induced liver injury: Interactions between drug properties and host factors.

Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI.

J Hepatol. 2015 Aug;63(2):503-14. doi: 10.1016/j.jhep.2015.04.016. Epub 2015 Apr 22. Review.


Regulation of Liver Enriched Transcription Factors in Rat Hepatocytes Cultures on Collagen and EHS Sarcoma Matrices.

Borlak J, Singh PK, Rittelmeyer I.

PLoS One. 2015 Apr 22;10(4):e0124867. doi: 10.1371/journal.pone.0124867. eCollection 2015.


Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis.

Liu Z, Borlak J, Tong W.

Genome Med. 2014 Dec 2;6(12):94. doi: 10.1186/s13073-014-0094-2. eCollection 2014.


Whole genome transcript profiling of drug induced steatosis in rats reveals a gene signature predictive of outcome.

Sahini N, Selvaraj S, Borlak J.

PLoS One. 2014 Dec 3;9(12):e114085. doi: 10.1371/journal.pone.0114085. eCollection 2014.


Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.

Siegmund W, Modess C, Scheuch E, Methling K, Keiser M, Nassif A, Rosskopf D, Bednarski PJ, Borlak J, Terhaag B.

Br J Clin Pharmacol. 2015 Mar;79(3):501-13. doi: 10.1111/bcp.12522.


Recent advances in live cell imaging of hepatoma cells.

Salipalli S, Singh PK, Borlak J.

BMC Cell Biol. 2014 Jul 8;15:26. doi: 10.1186/1471-2121-15-26. Review.


Explanted diseased livers - a possible source of metabolic competent primary human hepatocytes.

Kleine M, Riemer M, Krech T, DeTemple D, Jäger MD, Lehner F, Manns MP, Klempnauer J, Borlak J, Bektas H, Vondran FW.

PLoS One. 2014 Jul 7;9(7):e101386. doi: 10.1371/journal.pone.0101386. eCollection 2014.


A rat toxicogenomics study with the calcium sensitizer EMD82571 reveals a pleiotropic cause of teratogenicity.

Hewitt PG, Singh PK, Kumar A, Gnewuch C, Liebisch G, Schmitz G, Borlak J.

Reprod Toxicol. 2014 Aug;47:89-101. doi: 10.1016/j.reprotox.2014.06.006. Epub 2014 Jun 28.


A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.

Chen M, Tung CW, Shi Q, Guo L, Shi L, Fang H, Borlak J, Tong W.

Arch Toxicol. 2014 Jul;88(7):1439-49. doi: 10.1007/s00204-014-1276-9. Epub 2014 Jun 11.


Predicting idiosyncratic drug-induced liver injury: some recent advances.

Chen M, Borlak J, Tong W.

Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):721-3. doi: 10.1586/17474124.2014.922871. Epub 2014 May 23.


How useful are clinical liver function tests in in vitro human hepatotoxicity assays?

Borlak J, Chougule A, Singh PK.

Toxicol In Vitro. 2014 Aug;28(5):784-95. doi: 10.1016/j.tiv.2014.03.006. Epub 2014 Mar 28.


Isolation and cultivation of metabolically competent alveolar epithelial cells from A/J mice.

Hansen T, Chougule A, Borlak J.

Toxicol In Vitro. 2014 Aug;28(5):812-21. doi: 10.1016/j.tiv.2014.03.009. Epub 2014 Mar 27.


Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes.

Sahini N, Borlak J.

Prog Lipid Res. 2014 Apr;54:86-112. doi: 10.1016/j.plipres.2014.02.002. Epub 2014 Mar 6. Review.


Toward predictive models for drug-induced liver injury in humans: are we there yet?

Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W.

Biomark Med. 2014;8(2):201-13. doi: 10.2217/bmm.13.146. Review.


Transcriptional defect of an inherited NKX2-5 haplotype comprising a SNP, a nonsynonymous and a synonymous mutation, associated with human congenital heart disease.

Reamon-Buettner SM, Sattlegger E, Ciribilli Y, Inga A, Wessel A, Borlak J.

PLoS One. 2013 Dec 20;8(12):e83295. doi: 10.1371/journal.pone.0083295. eCollection 2013.


A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice.

Del Vescovo V, Meier T, Inga A, Denti MA, Borlak J.

PLoS One. 2013 Nov 12;8(11):e78870. doi: 10.1371/journal.pone.0078870. eCollection 2013.


Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury.

Borlak J, Chatterji B, Londhe KB, Watkins PB.

Genome Med. 2013 Sep 27;5(9):86. doi: 10.1186/gm493. eCollection 2013.


Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.

Chen M, Hong H, Fang H, Kelly R, Zhou G, Borlak J, Tong W.

Toxicol Sci. 2013 Nov;136(1):242-9. doi: 10.1093/toxsci/kft189. Epub 2013 Aug 31.


Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model.

Karra N, Nassar T, Ripin AN, Schwob O, Borlak J, Benita S.

Small. 2013 Dec 20;9(24):4221-36. doi: 10.1002/smll.201301417. Epub 2013 Jul 21.


A discriminative approach for unsupervised clustering of DNA sequence motifs.

Stegmaier P, Kel A, Wingender E, Borlak J.

PLoS Comput Biol. 2013;9(3):e1002958. doi: 10.1371/journal.pcbi.1002958. Epub 2013 Mar 21.


The liver toxicity knowledge base: a systems approach to a complex end point.

Chen M, Zhang J, Wang Y, Liu Z, Kelly R, Zhou G, Fang H, Borlak J, Tong W.

Clin Pharmacol Ther. 2013 May;93(5):409-12. doi: 10.1038/clpt.2013.16. Epub 2013 Jan 25.


Supplemental Content

Loading ...
Support Center